Fluoroquinolone Antibiotics: Microbiology, Pharmacokinetics and Clinical Use

Drugs

Volumn 36, Issue 2, 1988, Pages 193-228

  Paton, J H ^a   Reeves, D S ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ENOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN;

ANAEROBIC BACTERIUM; CELL CULTURE; DRUG RESISTANCE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN EXPERIMENT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MYCOBACTERIUM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTI-INFECTIVE AGENTS, QUINOLONE; BACTERIA; BACTERIAL INFECTIONS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; HALF-LIFE; HUMAN;

EID: 0023813325     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198836020-00004     Document Type: Review

References (267)

1. Phase I study on AM-715
2. The pharmacokinetics and tissue penetration of norfloxacin
3. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin
4. Clinical experience with ciprofloxacin in the USA
5. In-vitro activity of newer quinolones against aerobic bacteria
6. Activities of new quinolone derivatives against genital pathogens
7. Single doses of ofloxacin in uncomplicated gonorrhoea
8. Ciprofloxacin: an overview of adverse experiences
9. Overview of clinical experience with ciprofloxacin
10. Ciprofloxacin (4-quinolone) and Mycobacterium leprae
11. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin and oxolinic acid after in vitro selection of resistant populations
12. In vitro activity of ciprofloxacin against Gram-positive cocci
13. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid
14. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid
15. Bismuth/ofloxacin combination for duodenal ulcer
16. Metabolism of ciprofloxacin in man
17. A review of urinary tract infection in the elderly
18. Dose regimen of quinolone in reduced renal function
19. Norfloxacin penetration in human renal and prostatic tissue
20. Vergleichende Untersuchung von enoxacin mit Amoxicillin bei der akuten unkomplizierten Zystitis der Frau
21. Ofloxacin versus trimethoprim sulphamethoxazole in acute cystitis
22. The pharmacokinetics of ciprofloxacin in patients with impaired renal function
23. Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections
24. Norfloxacin in prostatitis: correlation between HPLC tissue concentrations and clinical results
25. Bactericidal intraprostatic concentrations of norfloxacin
26. Biotransformation von ausgewählten Gyrasehemmern
27. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis
28. Penetration of pefloxacin in human heart valves
29. The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection
30. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers
31. Ciprofloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
32. Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in vitro and in-vivo comparison
33. Resistance to ciprofloxacin
34. In vitro activity of C1-919 (AT2266), an oral antipseudomonal compound
35. Emergence of ofloxacin resistant Citrobacter freundii and Pseudomonas maltophilia after ofloxacin therapy
36. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new β-lactams, aminoglycosides and trimethoprim
37. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria
38. In vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams
39. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers
40. In-vitro susceptibility of mycobacteria to ciprofloxacin
41. Diffusion of ofloxacin into human lung tissue
42. Treatment of penicillin-resistant gonorrhoea with oral norfloxacin
43. The pharmacokinetics and tissue penetration of ciprofloxacin
44. Development of resistance to ofloxacin
45. Nalidixic acid: an antibacterial paradox
46. Nalidixic acid and bacterial chromosome replication
47. The effect of R-factor plasmids on host-cell respones to nalidixic acid. 1. Increased susceptibility of nalidixic acid-sensitive hosts
48. The inoculum effect with Gram-negative bacteria in vitro and in vivo
49. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis
50. Penetration of ofloxacin from blood to sputum
51. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study
52. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulphamethoxazole and colistin
53. The diffusion of pefloxacin into bone and the treatment of osteomyelitis
54. The new quinolones and their combinations with other agents for therapy of severe infections
55. Dosage of intravenous ciprofloxacin
56. Treatment of chronic salmonella carriers with ciprofloxacin
57. Morphological and biochemical changes in Escherichia coli after exposure to ciprofloxacin
58. Pharmacokinetics of ofloxacin in patients on haemodialysis treatment
59. Transfer kinetics of pefloxacin into cerebro-spinal fluid after one hour iv infusion of 400mg in man
60. Dose ranging study and constant infusion evaluation of ciprofloxacin
61. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function
62. In vitro activity of enoxacin against aminoglycoside-resistant Gram-negative bacilli and other clinical isolates
63. Use of norfloxacin in the treatment of acute diarrheal disease
64. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies
65. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent
66. Treatment of multiresistant Salmonella typhi with oral ciprofloxacin
67. In vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin
68. In vitro activity of ciprofloxacin (Bay 09867)
69. Treatment of skin and soft tissue infections with oral ciprofloxacin
70. Adverse reactions associated with quinolones
71. Comparative in vitro studies with 4-quinolone antimicrobials
72. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulareg1101
73. Pharmacokinetics of norfloxacin in renal failure
74. Ciprofloxacin concentrations in bone and muscle after oral dosing
75. Penetration of enoxacin into bronchial secretions
76. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400mg bid) in young healthy volunteers
77. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function
78. Treatment of complicated urinary tract infections with ciprofloxacin
79. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.
80. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity
81. DNA gyrase: an enzyme that introduces superhelical turns into DNA
82. Efficacy and tolerance of oral ofloxacin in treating various infections
83. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic Gram-negative bacilli
84. In-vitro susceptibility of Pseudomonas pseudomallei to DNA gyrase inhibitors
85. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin
86. In vitro activity of ciprofloxacin against Brucella melitensis.
87. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals
88. Susceptibility of Eikenella corrodens to newer and older quinolones
89. Multiple dose pharmacokinetics and safety of ciprofloxacin in normal volunteers
90. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers
91. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens
92. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU 28965 (a new macrolide) and other agents against enteropathogens
93. Clinical efficacy of ofloxacin in lower respiratory tract infections: a multicentre study
94. Activities of newer quinolones against Legionella group organisms
95. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of Gram-negative rods and staphylococci isolated from infected hospitalised patients
96. Comparative trial of norfloxacin and trimethoprim-sulphamethoxazole in the treatment of women with localised acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora
97. An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections
98. Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophila pneumonia
99. Comparative in-vitro activity of quinolone carboxylic acids against Proteeae
100. Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women
101. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, enoxacin, and nalidixic acid against Chlamydia trachomatis.
102. Clinical efficacy of ciprofloxacin therapy for Gram-negative bacillary osteomyelitis
103. Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity
104. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis
105. Reduced enterai absorption of ciprofloxacin in the presence of antacids
106. Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function
107. Norfloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use
108. Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function —some preliminary results
109. Ciprofloxacin-resistant Staphylococcus aureus,
110. Comparative in vitro activity of ciprofloxacin against non-fermenters
111. In vitro antibacterial activity of AM-715, a new nalidixic acid analog
112. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis
113. The efficacy and safety of ciprofloxacin and ofloxacin in the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis
114. Lack of emergence of resistant fecal flora during successful prophylaxis of travelers’ diarrhoea with norfloxacin
115. Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections
116. Side effects of ofloxacin in clinical trials and in postmarketing surveillence
117. In vitro activity of ciprofloxacin against Gram-positive bacteria: an overview
118. Biliary tract excretion of ofloxacin in man
119. Comparative evaluation of ciprofloxacin, enoxacin and ofloxacin in experimental Pseudomonas aeruginosa pneumonia
120. The comparative in-vitro activity of eight newer quinolones and nalidixic acid
121. The in vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid
122. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin
123. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients
124. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin
125. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin
126. Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients
127. The pharmacokinetics of ofloxacin in healthy adult male volunteers
128. Oral ciprofloxacin therapy for Gram-negative bacillary osteomyelitis
129. In-vitro activity of pefloxacin compared with six other quinolones
130. The SOS regulatory system of E. coli.
131. Cleavage of DNA by mammalian DNA topoisomerase II
132. The pharmacokinetics and tissue penetration of ofloxacin
133. Pharmacokinetics of ofloxacin after parenteral and oral administration
134. Single dose ciprofloxacin for the treatment of gonococcal infection in men
135. Clinical experience with ofloxacin in upper and lower urinary tract infections: a comparison with cotrimoxazole and nitrofurantoin
136. The use of quinolones in respiratory tract infections
137. Pefloxacin in acute exacerbation of chronic bronchitis
138. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents
139. A homogeneous type II DNA topoisomerase from HeLa cell nuclei
140. Ofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use
141. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys and humans
142. In vitro activity of ciprofloxacin combined with azlocillin
143. Site-specific cleavage of DNA by E. coli DNA gyrase
144. Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization
145. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1
146. Corynebacterium jeikeium (Group JK) resistance to ciprofloxacin emerging during therapy
147. Treatment of chancroid with ciprofloxacin: a prospective, randomized clinical trial
148. A profile of human pharmacokinetics and clinical studies of the gyrase inhibitor enoxacin
149. In vitro-Aktivität, Serum-, Urin-und Prostataadenom-Gewebekonzentrationen von Ofloxacin bei urologischen Patienten mit komplizierten Harnwegsinfektionen
150. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections
151. In vitro antibacterial properties of AT-2266, a new pyridone carboxylic acid
152. Pharmacological properties of AT-2266
153. Clinical pharmacokinetics of the newer antibacterial 4-quinolones
154. The antimicrobial spectrum of norfloxacin
155. A comparative study of ciprofloxacin and trimethoprim in the treatment of urinary tract infections in geriatric patients
156. A double blind study comparing two dosages of enoxacin for the treatment of uncomplicated urogenital gonorrhoea
157. Ciprofloxacin in the treatment of gonorrhoea and non-gonococcal urethritis
158. Antimycoplasmal activity of ofloxacin (DL-8280)
159. Interaction between ciprofloxacin and vancomycin against staphylococci
160. Multiply resistant Salmonella typhimurium septicaemia in an immuno-compromised patient successfully treated with ciprofloxacin
161. Activity of ofloxacin and perfloxacin against mycobacterium leprae in mice
162. In vitro activities of the spectinomycin analogue U-63366 and four quinolone derivatives against Neisseria gonorrhoeae
163. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis
164. Animal models: the in-vitro evaluation of ciprofloxacin
165. Bacterial mutagenicity and the 4-quinolones
166. Quinolone/ureidopenicillin cross-resistance
167. Effect of dose size on bioavailability of ciprofloxacin
168. In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867)
169. Open, prospective study of the clinical efficacy of ciprofloxacin
170. Enoxacin concentration in human prostatic tissue after oral administration
171. Ciprofloxacin increases serum theophylline levels
172. Treatment of respiratory tract infections with ciprofloxacin
173. Reduced virulence in ciprofloxacin resistant variants of Pseudomonas aeruginosa strains
174. The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibacterials
175. The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity
176. In vitro studies with ciprofloxacin, a new 4-quinolone compound
177. Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study
178. Comparative in vitro activities of selected antimicrobial agents against Aeromonas species and Plesiomonas shigelloides
179. Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland
180. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro
181. Ciprofloxacin treatment of Staphylococcus aureus infections
182. Ciprofloxacin resistant pseudomonas
183. Ciprofloxacin: comparative data in cystic fibrosis
184. Ciprofloxacin in the treatment of pseudomonas infection in cystic fibrosis patients
185. Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections
186. Oral ciprofloxacin in resistant urinary tract infections
187. Ofloxacin in respiratory tract infections: a review of the results of clinical trials in Japan
188. Pefloxacin concentrations in human aqueous humour and lens
189. Overview of preclinical studies with ciprofloxacin
190. Selection of multiple antibiotic resistance by quinolones, β-lactams and aminoglycosides with special reference to cross-resistance between unrelated drug classes
191. Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens
192. In vitro and in vivo activity of DL-8280, a new oxazine derivative
193. Klinische Erfahrungen bei Behandlung von Harnwegsinfektionen bei Querschrullgelämten mit Norfloxacin
194. Worldwide clinical data on efficacy and safety of ciprofloxacin
195. Ciprofloxacin: review of potential toxicologic effects
196. Ciprofloxacin therapy in cystic fibrosis
197. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa
198. Effect of co-medication on absorption of ciprofloxacin and ofloxacin from gastrointestinal tract
199. Clinical experience with quinolones —overview
200. Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis
201. The antimicrobial spectrum of the quinolones
202. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA
203. Mechanism of renal excretion of AM-715, a new quinolone-carboxylic acid derivative in rabbits, dogs and humans
204. Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents
205. Oral ciprofloxacin therapy for osteomyelitis caused by aerobic Gram-negative bacilli
206. Ciprofloxacin-resistant staphylococci
207. Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients
208. Awakening the slumbering potential of the 4-quinolone antibacterials
209. Ciprofloxacin in cystic fibrosis
210. The effect of ciprofloxacin on methicillin resistant Staphylococcus aureus
211. Effect of food on enoxacin absorption
212. Interaction between quinolones and caffeine
213. Quinolones in the treatment of gonorrhoea and Chlamydia trachomatis infections
214. Mechanism of action of nalidixic acid: purification of Escherichia coli Nal A gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme
215. Norfloxacin disposition after sequentially increasing oral doses
216. Penetration of ofloxacin into bronchial secretions
217. Diffusion of enoxacin into the cerebrospinal fluid in dogs with healthy meninges and with experimental meningitis
218. New approaches to the treatment of urinary tract infections
219. Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400mg twice daily for 14 days
220. Therapeutic effect of a new antibacterial substance ofloxacin (DL 8280) on pulmonary tuberculosis
221. Penetration of ciprofloxacin into cerebrospinal fluid
222. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinolone derivatives
223. Comparative double-blind study of 200 and 400mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhoea in males
224. Resistance of Neisseria gonorrhoea to enoxacin
225. The comparative in vitro activity of twelve 4-quinolone antimicrobials against Haemophilus ducreyi.
226. Interactions between twisted DNAs and enzymes: the effects of superhelical turns
227. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function
228. Treatment of chronic bacterial prostatitis with ciprofloxacin: results of a one-year follow-up study
229. Inhibition of R-plasmid transfer in Escherichia coli by 4-quinolones
230. Metabolism of 4-quinolones
231. A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure
232. Enoxacin decreases the clearance of theophylline in man
233. The influence of quinolone derivatives on theophylline clearance
234. Ciprofloxacin and co-trimoxazole in urinary tract infection
235. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers
236. Norfloxacin for prevention of bacterial infections in granulocytopenic patients
237. Norfloxacin —a review of pharmacology and tissue penetration
238. In vitro activity of enoxacin (CI-919), a new quinolone derivative, compared with that of other antimicrobial agents
239. In vitro activity of Bay 09867, a new quinolone derivative, compared with those of other antimicrobial agents
240. Tissue penetration and metabolism of ciprofloxacin
241. The comparative pharmacokinetics of five quinolones
242. Norfloxacin versus placebo for prophylaxis against travellers’ diarrhoea
243. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers
244. Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis
245. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro
246. Ciprofloxacin for soft tissue infections
247. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin